Anthony P. Adamis - 23 Jun 2024 Form 4 Insider Report for EyePoint Pharmaceuticals, Inc. (EYPT)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
25 Jun 2024, 16:16:53 UTC
Prior SEC filing
09 Jan 2024
Next SEC filing
18 Mar 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Ron Honig, Attorney-in-Fact

Key filing fact

Anthony P. Adamis filed Form 4 for EyePoint Pharmaceuticals, Inc. (EYPT) on 25 Jun 2024.

Key facts

  • This page summarizes Anthony P. Adamis's Form 4 filing for EyePoint Pharmaceuticals, Inc. (EYPT).
  • 2 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 25 Jun 2024, 16:16.

Change

  • Previous filing in this sequence was filed on 09 Jan 2024.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

EYPT transaction

Common Stock

Options Exercise

Transaction value
$0
Shares
+2,000
Change %
+100%
Price
$0.000000
Shares after
4,000
Date
23 Jun 2024
Ownership
Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

EYPT transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
$0
Shares
-2,000
Change %
-50%
Price
$0.000000
Shares after
2,000
Date
23 Jun 2024
Ownership
Direct
Underlying class
Common Stock
Underlying amount
2,000
Exercise price
$0.000000
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The restricted stock units vests in three ratable annual installments beginning June 23, 2023.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .